BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/26/2020 8:54:27 AM | Browse: 935 | Download: 1842
 |
Received |
|
2020-08-28 23:43 |
|
Peer-Review Started |
|
2020-08-28 23:43 |
|
First Decision by Editorial Office Director |
|
2020-10-05 23:14 |
|
Return for Revision |
|
2020-10-05 23:14 |
|
Revised |
|
2020-10-12 17:49 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-11-06 08:24 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-11-10 17:35 |
|
Articles in Press |
|
2020-11-10 17:35 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-11-23 12:13 |
|
Publish the Manuscript Online |
|
2020-11-26 08:54 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Nso Nso, Daniel Antwi-Amoabeng, Bryce D Beutler, Mark B Ulanja, Jasmine Ghuman, Ahmed Hanfy, Joyce Nimo-Boampong, Sirri Atanga, Rajkumar Doshi, Sostanie Enoru and Nageshwara Gullapalli |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Bryce D Beutler, MD, Doctor, Doctor, Department of Radiology, University of Southern California, Keck School of Medicine, 1500 San Pablo St., 2nd Floor, Los Angeles, CA 90033, United States. brycebeutler@hotmail.com |
| Key Words |
Atrial fibrillation; Cancer; Immune checkpoint inhibitors; Immunotherapy; Cardiovascular adverse events; Pericardial effusion |
| Core Tip |
Cardiovascular immune-related adverse events (irAEs) are rare but potentially life-threatening complications that can occur in patients receiving immune checkpoint inhibitor (ICI) therapy. The most common ICI-associated adverse events are atrial fibrillation, myocarditis, and pericardial effusion. Risk factors for cardiovascular irAEs include treatment with combination immunotherapy, male sex, and a history of cardiac disease. Ongoing post-market surveillance is imperative to characterize long-term risks and improve outcomes among patients receiving ICIs. |
| Publish Date |
2020-11-26 08:54 |
| Citation |
Nso N, Antwi-Amoabeng D, Beutler BD, Ulanja MB, Ghuman J, Hanfy A, Nimo-Boampong J, Atanga S, Doshi R, Enoru S, Gullapalli N. Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis. World J Cardiol 2020; 12:(11): 584-598 |
| URL |
https://www.wjgnet.com/1949-8462/full/v12/i11/584.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v12.i11.584 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
